MapLight Therapeutics, Inc. — Investor Relations & Filings

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for central nervous system (CNS) disorders. The company leverages a proprietary platform rooted in circuit-level neuroscience to identify and modulate specific neural circuits associated with disease pathology. This approach is designed to create more effective and better-tolerated treatments by addressing the underlying circuit dysfunction rather than broad neurotransmitter imbalances. MapLight’s development pipeline includes therapeutic candidates for Autism Spectrum Disorder, Parkinson’s Disease, and Schizophrenia, with several programs in clinical and preclinical stages. The company aims to redefine the standard of care for patients suffering from complex neuropsychiatric and neurological conditions through its circuit-based discovery engine.